Curis (NASDAQ:CRIS) Shares Down 2.3% – Time to Sell?

Curis, Inc. (NASDAQ:CRIS) shares traded down 2.3% on Friday . The stock traded as low as $3.85 and last traded at $3.86. 92,881 shares were traded during trading, an increase of 123% from the average session volume of 41,684 shares. The stock had previously closed at $3.95.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Curis in a report on Friday, November 15th.

Curis Price Performance

The company has a 50 day moving average price of $4.60 and a 200 day moving average price of $5.98. The firm has a market cap of $32.68 million, a PE ratio of -0.49 and a beta of 3.34.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in CRIS. Focused Wealth Management Inc boosted its stake in shares of Curis by 63.1% in the third quarter. Focused Wealth Management Inc now owns 54,066 shares of the biotechnology company’s stock valued at $291,000 after buying an additional 20,908 shares in the last quarter. Point72 Asset Management L.P. lifted its holdings in Curis by 795.5% in the second quarter. Point72 Asset Management L.P. now owns 108,356 shares of the biotechnology company’s stock valued at $748,000 after acquiring an additional 96,256 shares during the period. Finally, Vanguard Group Inc. boosted its position in shares of Curis by 4.8% during the 1st quarter. Vanguard Group Inc. now owns 218,573 shares of the biotechnology company’s stock worth $2,376,000 after purchasing an additional 10,097 shares in the last quarter. 29.97% of the stock is owned by hedge funds and other institutional investors.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.